Cytokinetics, Incorporated (CYTK)
After hours:
| Previous close | 64.80 |
| Open | 65.11 |
| Bid | 65.29 x 200 |
| Ask | 65.40 x 400 |
| Day's range | 64.50 - 66.07 |
| 52-week range | 25.98 - 110.25 |
| Volume | |
| Avg. volume | 2,028,901 |
| Market cap | 6.833B |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.45 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 95.06 |
GlobeNewswireCytokinetics to Announce First Quarter Results on May 8, 2024
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the Invest
- GlobeNewswire
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstructi
GuruFocus.comEVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
Cytokinetics Inc (NASDAQ:CYTK), a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for muscle diseases, has reported an insider sale according to a recent SEC filing.
